Known targets — ChEMBL curated mechanism
ABCC9ABL1ACEACHEACVR1ADORA1ADORA2AADORA2BADORA3ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALOX5ATP4AATP4BBCRBTKCACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGCRBNCUL4ACXCR1CXCR2DDB1DDCDHFRDPP4DRD2DRD3DRD4EGFRERBB2ERBB4ESR1ESR2FDPSFKBP1AFLT1FLT3FLT4GARTGHSRGRIA1GRIA2GRIA3GRIA4GRIK1GRIK2GRIK3GRIK4GRIK5GRIN2AGSK3AGSK3BHDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IDH1IDH2IMPA1ITGA2BITGB3JAK1JAK2JAK3KCNJ11KCNK3KCNK9KDRKITMEN1METMMP1MMP13MMP7MMP8NANOD2NS5bODC1OPG057OPRD1OPRK1OPRM1PPARP1PARP2PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PKLRPPARDPPATPTGS1PTGS2RBX1ROCK1ROCK2RRM1RRM2RRM2BSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC10A2SLC5A2SLC6A2SLC6A3SLC6A4SLC9A3SYKTACR1THRATHRBTOP1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYK2TYMSVDRampCblablaT-3blaT-4blaT-5blaT-6blaUOE-1dacAdacBdacCfolAfolPftsIgyrAgyrBileSmecAmrcAmrcBmrdAparCparEpbp2pbp4pbpApbpFrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUthyAykgMykgO
The experimentally established mechanism targets of Water. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB known ✓ | P10828 | 1/20 | 0.36 |
| ▸ | MEN1 known ✓ | O00255 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 2/20 | 0.63 |
| ▸ | CA2 | P00918 | 2/20 | 0.63 |
| ▸ | RAD51 | Q06609 | 4/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.54 |
| ▸ | MAPT | P10636 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
| ▸ | USP2 | O75604 | 2/20 | 0.54 |
| ▸ | LTA | P01374 | 2/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.54 |
| ▸ | HPGD | P15428 | 2/20 | 0.54 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.54 |
| ▸ | P2RY6 | Q15077 | 3/20 | 0.45 |
| ▸ | MIF | P14174 | 2/20 | 0.45 |
| ▸ | PLCG1 | P19174 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | RAD1 | O60671 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1483567 | 0.98 | CA1 (0.66) | CA1CA2RAD51TDP1HSD17B10 | |
| SCHEMBL483832 | 0.81 | CA1 (0.70) | CA1CA2RAD51TDP1HSD17B10 | |
| SCHEMBL4350712 | 0.80 | RAD51 (0.55) | CA1CA2RAD51TDP1HSD17B10 | |
| SCHEMBL3895085 | 0.80 | RAD51 (0.50) | CA1CA2RAD51TDP1HSD17B10 | |
| SCHEMBL31148855 | 0.79 | CYP3A4 (0.48) | CA1CA2RAD51TDP1HSD17B10 | |
| Water SCHEMBL3903037 | 0.78 | CA1 (0.61) | CA1CA2RAD51TDP1HSD17B10 | |
| SCHEMBL10907354 | 0.78 | RAD51 (0.53) | CA1CA2RAD51TDP1HSD17B10 | |
| SCHEMBL31315339 | 0.78 | CA1 (0.66) | CA1CA2RAD51TDP1HSD17B10 | |
| SCHEMBL2891113 | 0.78 | CA1 (0.66) | CA1CA2RAD51TDP1HSD17B10 | |
| SCHEMBL668791 | 0.78 | CA1 (0.66) | CA1CA2RAD51TDP1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3543226-B1 | NOVEL IMAGING COMPOSITION AND USES THEREOF | UNIV MELBOURNE (AU) | 2024-03-06 | — | — | EP | disclosed |
| US-7572459-B2 | Prevention infections in humans, animals | STARPHARMA PTY LTD. (AU) | 2009-08-11 | — | — | US | disclosed |
| EP-1113806-B1 | ANIONIC OR CATIONIC DENDRIMER ANTIMICROBIAL OR ANTIPARASITIC COMPOSITIONS | STARPHARMA PTY LTD (AU) | 2007-09-05 | — | — | EP | disclosed |
| EP-0765357-B9 | ANTIVIRAL DENDRIMERS | STARPHARMA PTY LTD (AU) | 2006-08-16 | — | — | EP | disclosed |
| EP-0927217-B1 | ANGIOGENIC INHIBITORY COMPOUNDS | STARPHARMA PTY LTD (AU) | 2006-05-03 | — | — | EP | disclosed |
| EP-0765357-B8 | ANTIVIRAL DENDRIMERS | STARPHARMA PTY LTD (AU) | 2006-03-08 | — | — | EP | disclosed |
| EP-0765357-B1 | ANTIVIRAL DENDRIMERS | BIOMOLECULAR RES INST LTD (AU) | 2005-12-14 | — | — | EP | disclosed |
| US-6740635-B2 | AIDS THERAPY, RESPIRATORY SYNCYTIAL VIRUS | BIOMOLECULAR RESEARCH INSTITUTE LTD. (AU) | 2004-05-25 | — | — | US | disclosed |
| EP-1113805-A4 | INHIBITION OF TOXIC MATERIALS OR SUBSTANCES USING DENDRIMERS | STARPHARMA LTD (AU) | 2004-05-19 | — | — | EP | disclosed |
| US-20030129158-A1 | Anionic or cationic dendrimer antimicrobial or antiparasitic compositions | STARPHARMA LIMITED | 2003-07-10 | — | — | US | disclosed |
| US-6190650-B1 | FOR PROPHYLAXIS AND THERAPY OF VIRAL DISEASES IN HUMANS AND ANIMALS | BIOMOLECULAR RESEARCH INSTITUTE LTD. (AU) | 2001-02-20 | — | — | US | disclosed |
| WO-2000015240-A1 | ANIONIC OR CATIONIC DENDRIMER ANTIMICROBIAL OR ANTIPARASITIC COMPOSITIONS | STARPHARMA LIMITED (AU) | 2000-03-23 | — | — | WO | disclosed |
| WO-2000015239-A1 | INHIBITION OF TOXIC MATERIALS OR SUBSTANCES USING DENDRIMERS | STARPHARMA LIMITED (AU) | 2000-03-23 | — | — | WO | disclosed |
| EP-0928306-A1 | ANTIVIRAL LINEAR POLYMERS | BIOMOLECULAR RESEARCH INSTITUTE LTD. (AU) | 1999-07-14 | — | — | EP | disclosed |
| EP-0927217-A1 | ANGIOGENIC INHIBITORY COMPOUNDS | BIOMOLECULAR RESEARCH INSTITUTE LTD. (AU) | 1999-07-07 | — | — | EP | disclosed |
| WO-1998003573-A1 | ANGIOGENIC INHIBITORY COMPOUNDS | BIOMOLECULAR RESEARCH INSTITUTE LTD. (AU) | 1998-01-29 | — | — | WO | disclosed |
| WO-1998003572-A1 | ANTIVIRAL LINEAR POLYMERS | BIOMOLECULAR RESEARCH INSTITUTE LTD. (AU) | 1998-01-29 | — | — | WO | disclosed |
| EP-0765357-A4 | ANTIVIRAL DENDRIMERS | BIOMOLECULAR RES INST LTD (AU) | 1997-07-30 | — | — | EP | disclosed |
| EP-0765357-A1 | ANTIVIRAL DENDRIMERS | BIOMOLECULAR RESEARCH INSTITUTE LTD. (AU) | 1997-04-02 | — | — | EP | disclosed |
| WO-1995034595-A1 | ANTIVIRAL DENDRIMERS | BIOMOLECULAR RESEARCH INSTITUTE LTD. (AU) | 1995-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030129158-A1 | Anionic or cationic dendrimer antimicrobial or antiparasitic compositions | FUT6, B3GNT2, SIGLEC7 | THRB 3991/4885MEN1 653/4885CA1 2006/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.